Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of ...

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

In some good news for the US vaccines developer, whose stock has fallen 66% in the past 12 months, Moderna on Friday ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Moderna (MRNA) to $38 from $70 and keeps an Equal Weight rating on the ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) ...

This diverse pipeline exemplifies Moderna's road map to extend its mRNA technology into new categories, positioning itself as a more diversified and mature commercial-stage biotech company.